Global Meningococcal Polysaccharide Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Meningococcal Polysaccharide Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Meningococcal polysaccharide diphtheria conjugate vaccine is an active immunizing agent used to prevent infection by certain groups of meningococcal bacteria.
Meningococcal Polysaccharide Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Meningococcal Polysaccharide Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from 6 Months-15Year and over 3 Year are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Meningococcal Polysaccharide Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Meningococcal Polysaccharide Vaccine key manufacturers include Sanofi, Bio-Med, CanSinoBIO, Walvax Biotechnology, Chongqing Zhifei Biological, Chengdu Kanghua Biological Products, Changsheng Biotechnology and CanSinoBIO, etc. Sanofi, Bio-Med, CanSinoBIO are top 3 players and held % sales share in total in 2022.
Meningococcal Polysaccharide Vaccine can be divided into Polysaccharide Meningtitis AC and Meningitis ACYW, etc. Polysaccharide Meningtitis AC is the mainstream product in the market, accounting for % sales share globally in 2022.
Meningococcal Polysaccharide Vaccine is widely used in various fields, such as 6 Months-15Year, over 3 Year, over 2 Year and over 3 Months, etc. 6 Months-15Year provides greatest supports to the Meningococcal Polysaccharide Vaccine industry development. In 2022, global % sales of Meningococcal Polysaccharide Vaccine went into 6 Months-15Year filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Meningococcal Polysaccharide Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sanofi
Bio-Med
CanSinoBIO
Walvax Biotechnology
Chongqing Zhifei Biological
Chengdu Kanghua Biological Products
Changsheng Biotechnology
CanSinoBIO
Segment by Type
Polysaccharide Meningtitis AC
Meningitis ACYW
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Meningococcal Polysaccharide Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Meningococcal Polysaccharide Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Meningococcal Polysaccharide Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Meningococcal Polysaccharide Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Meningococcal Polysaccharide Vaccine introduction, etc. Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Meningococcal Polysaccharide Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Meningococcal Polysaccharide Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Meningococcal Polysaccharide Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from 6 Months-15Year and over 3 Year are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Meningococcal Polysaccharide Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Meningococcal Polysaccharide Vaccine key manufacturers include Sanofi, Bio-Med, CanSinoBIO, Walvax Biotechnology, Chongqing Zhifei Biological, Chengdu Kanghua Biological Products, Changsheng Biotechnology and CanSinoBIO, etc. Sanofi, Bio-Med, CanSinoBIO are top 3 players and held % sales share in total in 2022.
Meningococcal Polysaccharide Vaccine can be divided into Polysaccharide Meningtitis AC and Meningitis ACYW, etc. Polysaccharide Meningtitis AC is the mainstream product in the market, accounting for % sales share globally in 2022.
Meningococcal Polysaccharide Vaccine is widely used in various fields, such as 6 Months-15Year, over 3 Year, over 2 Year and over 3 Months, etc. 6 Months-15Year provides greatest supports to the Meningococcal Polysaccharide Vaccine industry development. In 2022, global % sales of Meningococcal Polysaccharide Vaccine went into 6 Months-15Year filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Meningococcal Polysaccharide Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sanofi
Bio-Med
CanSinoBIO
Walvax Biotechnology
Chongqing Zhifei Biological
Chengdu Kanghua Biological Products
Changsheng Biotechnology
CanSinoBIO
Segment by Type
Polysaccharide Meningtitis AC
Meningitis ACYW
Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Meningococcal Polysaccharide Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Meningococcal Polysaccharide Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Meningococcal Polysaccharide Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Meningococcal Polysaccharide Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Meningococcal Polysaccharide Vaccine introduction, etc. Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Meningococcal Polysaccharide Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices